Form 6-K GENETIC TECHNOLOGIES For: Dec 19

Date: December�19, 2014

�

�

�

�

GENETIC TECHNOLOGIES LIMITED

�

�

�

�

�

By:

/s/ Bronwyn Christie

�

�

Name: Bronwyn Christie

�

�

Title: Company Secretary

Exhibit

�

Description�of�Exhibit

�

�

�

99.1

�

ASX Announcement, December�19, 2014

�

�

�

99.2

�

Appendix 3B, December�19, 2014

Ms.�Alison Mew

Mr.�Eutillio Buccilli

Candice Knoll (USA)

Chief Executive Officer

Chief Operating Officer�&

Blueprint Life Science Group

�

Chief Financial Officer

+1 (415) 375 3340, Ext. 105

Genetic Technologies Limited

Genetic Technologies Limited

�

+61 3 8412 7009

+ 61 3 8412 7050

�

�

�

�

�

�

�

�

1

�

+Class�of +securities issued or to be issued

�

Ordinary shares

�

�

�

�

�

2

�

Number of +securities issued or to be issued (if known) or maximum number which may be issued

�

7,848,862 in respect of conversion of 100,000 convertible notes

210,737 in respect of interest accrued under the convertible note

�

�

�

�

�

3

�

Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

�

Fully paid ordinary shares

4

�

Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

�

If the additional securities do not rank equally, please state:

������������������ the date from which they do

������������������ the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

������������������ the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

�

Yes

�

�

�

�

�

5

�

Issue price or consideration

�

The face value of Convertible Notes converted at $1.00 per note ($100,000), plus interest accrued ($2,685).There will be no additional funds received by the Company for the Notes becoming Convertible Notes.

�

�

�

�

�

6

�

Purpose of the issue

(If issued as consideration for the acquisition of assets, clearly identify those assets)

�

To provide the Company with general working capital and to fund the continuing commercialisation and to facilitate the acceptance and growth of the Company�s flagship lead breast cancer risk test BREVAGenplusTM.

�

�

�

�

�

6a

�

Is the entity an +eligible entity that has obtained security holder approval under rule�7.1A?

�

If Yes, complete sections 6b � 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i

�

No

�

�

�

�

�

6b

�

The date the security holder resolution under rule�7.1A was passed

�

Not applicable

�

�

�

�

�

6c

�

Number of +securities issued without security holder approval under rule�7.1

�

Not applicable

�

�

�

�

�

6d

�

Number of +securities issued with security holder approval under rule�7.1A

�

Not applicable

6e

�

Number of +securities issued with security holder approval under rule�7.3, or another specific security holder approval (specify date of meeting)

�

Not applicable

�

�

�

�

�

6f

�

Number of securities issued under an exception in rule�7.2

�

Not applicable

�

�

�

�

�

6g

�

If securities issued under rule�7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule�7.1A.3?� Include the issue date and both values.� Include the source of the VWAP calculation.

�

Not applicable

�

�

�

�

�

6h

�

If securities were issued under rule�7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

�

Not applicable

�

�

�

�

�

6i

�

Calculate the entity�s remaining issue capacity under rule�7.1 and rule�7.1A � complete Annexure 1 and release to ASX Market Announcements

�

110,956,555

�

�

�

�

�

7

�

Dates of entering +securities into uncertificated holdings or despatch of certificates

�

19 December�2014

�

�

�

�

�

�

�

�

�

Number

�

+Class

8

�

Number and +class of all +securities quoted on ASX (including the securities in section 2 if applicable)

�

820,849,917

�

Ordinary shares

�

�

�

�

Number

�

+Class

9

�

Number and +class of all +securities not quoted on ASX (including the securities in section 2 if applicable)

�

1,875,000

�

Options at $0.19, exp. 31/3/2016 (GTGAW)

�

�

�

�

1,000,000

�

Options at $0.20, exp. 31/7/2016 (GTGAM)

�

�

�

�

750,000

�

Options at $0.12, exp. 20/2/2017 (GTGAK)

�

�

�

�

2,650,000

�

Options at $0.14, exp. 29/8/2017 (GTGAO)

�

�

�

�

250,000

�

Options at $0.10, exp. 1/12/17 (GTGAQ)

�

�

�

�

500,000

�

Options at $0.10, exp. 25/1/18 (GTGAS)

�

�

�

�

750,000

�

Options at $0.105, exp. 11/7/18 (GTGAY)

�

�

�

�

6,875,000

�

Options at $0.04, exp. 31/5/19 (GTGAA)

�

�

�

�

1,600,000

�

Convertible Notes issued on 3 December�2014 (GTGAB)

�

�

�

�

143,333,333

�

Options at $0.015, exp. 2/12/2018 (GTGAC)

10

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

�

�

�

�

�

�

11

Is security holder approval required?

�

�

�

�

�

�

12

Is the issue renounceable or non-renounceable?

�

�

�

�

�

�

13

Ratio in which the +securities will be offered

�

�

�

�

�

�

14

+Class�of +securities to which the offer relates

�

�

�

�

�

�

15

+Record date to determine entitlements

�

�

�

�

�

�

16

Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?

�

�

�

�

�

�

17

Policy for deciding entitlements in relation to fractions

�

�

�

�

�

�

18

Names of countries in which the entity has +security holders who will not be sent new issue documents

�

Note: Security holders must be told how their entitlements are to be dealt with.

�

Cross reference: rule�7.7.

�

�

�

�

�

�

19

Closing date for receipt of acceptances or renunciations

�

�

�

�

�

�

20

Names of any underwriters

�

�

�

�

�

�

21

Amount of any underwriting fee or commission

�

�

�

�

�

�

22

Names of any brokers to the issue

�

�

�

�

�

�

23

Fee or commission payable to the broker to the issue

�

�

�

�

�

�

24

Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders

�

�

�

�

�

�

25

If the issue is contingent on +security holders� approval, the date of the meeting

�

�

26

Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled

�

�

�

�

�

�

27

If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders

�

�

�

�

�

�

28

Date rights trading will begin (if applicable)

�

�

�

�

�

�

29

Date rights trading will end (if applicable)

�

�

�

�

�

�

30

How do +security holders sell their entitlements in full through a broker?

�

�

�

�

�

�

31

How do +security holders sell part of their entitlements through a broker and accept for the balance?

�

�

�

�

�

�

32

How do +security holders dispose of their entitlements (except by sale through a broker)?

�

�

�

�

�

�

33

+Despatch date

�

�

34

Type of securities

(tick one)

�

�

�

�

�

�

(a)

x

Securities described in Part�1

�

�

�

�

�

�

(b)

o

All other securities

�

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Tick to indicate you are providing the information or documents

�

�

35

o

If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

�

�

�

�

�

36

o

If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories

1 - 1,000

1,001 - 5,000

5,001 - 10,000

10,001 - 100,000

100,001 and over

�

�

�

37

o

A copy of any trust deed for the additional +securities

38

Number of securities for which +quotation is sought

�

�

�

�

�

�

39

Class�of +securities for which quotation is sought

�

�

�

�

�

�

40

Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

�

If the additional securities do not rank equally, please state:

������������� the date from which they do

������������� the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

������������� the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

�

�

�

�

�

�

41

Reason for request for quotation now

�

Example: In the case of restricted securities, end of restriction period

�

(if issued upon conversion of another security, clearly identify that other security)

�

�

�

�

�

�

�

�

�

Number

�

+Class

42

Number and +class of all +securities quoted on ASX

�

�

�

�

�

(including the securities in clause 38)

�

�

�

�

�

�

�

�

�

�

�

�

�

�

Sign here:

�

�

Date: 19 December�2014

�

Chief Executive Officer

�

�

�

�

�

�

�

�

�

�

Print name:

Alison Mew

�

�

Step 1: Calculate �A�, the base figure from which the placement capacity is calculated

�

�

�

Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue

�

572,694,101

�

�

�

�

�

Add the following:

������������� Number of fully paid ordinary securities issued in that 12 month period under an exception in rule�7.2

������������� Number of fully paid ordinary securities issued in that 12 month period with shareholder approval

������������� Number of partly paid ordinary securities that became fully paid in that 12 month period

�

Note:

������������� Include only ordinary securities here � other classes of equity securities cannot be added

������������� Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed

������������� It may be useful to set out issues of securities on different dates as separate line items

�

�

�

�

313,509,896

�

�

�

�

�

Subtract the number of fully paid ordinary securities cancelled during that 12 month period

�

75,937,500

�

�

�

�

�

�A�

�

810,266,497

�

�

�

�

�

Step 2: Calculate 15% of �A�

�

�

�

�

�

�

�

�B�

�

0.15

[Note: this value cannot be changed]

�

�

�

�

�

Multiply �A� by 0.15

�

121,539,975

�

Step 3: Calculate �C�, the amount of placement capacity under rule�7.1 that has already been used

�

�

�

�

�

Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:

�

�

�

�

�

�

�

������������������ Under an exception in rule�7.2

�

�

�

�

�

�

�

������������������ Under rule�7.1A

�

�

�

�

�

�

�

������������������ With security holder approval under rule�7.1 or rule�7.4

�

�

�

�

�

�

�

Note:

�

�

�

������������������ This applies to equity securities, unless specifically excluded � not just ordinary securities

�

�

�

������������������ Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed

�

�

�

������������������ It may be useful to set out issues of securities on different dates as separate line items

�

�

�

�

�

�

�

�C�

�

10,583,420

�

�

�

�

�

Step 4: Subtract �C� from [�A� x �B�] to calculate remaining placement capacity under rule�7.1

�

�

�

�

�

�A� x 0.15

�

121,539,975

�

�

�

�

�

Note: number must be same as shown in Step 2

�

�

�

�

�

�

�

Subtract �C�

�

10,583,420

�

�

�

�

�

Note: number must be same as shown in Step 3

�

�

�

�

�

�

�

Total [�A� x 0.15] � �C�

�

110,956,555

�

�

�

�

�

�

�

[Note: this is the remaining placement capacity under rule 7.1]

�

Step 1: Calculate �A�, the base figure from which the placement capacity is calculated

�

�

�

�A�

�

�

�

�

�

Note: number must be same as shown in Step 1 of Part�1

�

�

�

�

�

Step 2: Calculate 10% of �A�

�

�

�

�

�

�D�

�

0.10

�

Note: this value cannot be changed

�

�

�

Multiply �A� by 0.10

�

�

�

�

�

Step 3: Calculate �E�, the amount of placement capacity under rule�7.1A that has already been used

Insert number of equity securities issued or agreed to be issued in that 12 month period under rule�7.1A

�

Notes:

������������� This applies to equity securities � not just ordinary securities

������������� Include here � if applicable � the securities the subject of the Appendix 3B to which this form is annexed

������������� Do not include equity securities issued under rule�7.1 (they must be dealt with in Part�1), or for which specific security holder approval has been obtained

������������� It may be useful to set out issues of securities on different dates as separate line items

�

�

�

�E�

�

Step 4: Subtract �E� from [�A� x �D�] to calculate remaining placement capacity under rule�7.1A

�

�

�

�A� x 0.10

�

Note: number must be same as shown in Step 2

�

�

�

�

�

Subtract �E�

�

�

�

�

�

Note: number must be same as shown in Step 3

�

�

�

�

�

Total [�A� x 0.10] � �E�

�

�

�

�

�

�

�

Note: this is the remaining placement capacity under rule�7.1A